Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis

Table 1 Baseline clinical characteristics of the study group, n (%)

Patient characteristics	Value (n = 30)
Age (median in years) (range)	65 (38-83)
Gender
Male	27 (90)
Female	3 (10)
Viral serology
Hepatitis B positive	5 (16.7)
Hepatitis C positive	5 (16.7)
Child-Pugh class at diagnosis
Child-Pugh class A	16 (53.3)
Child-Pugh class B	14 (46.7)
ALBI score (median) (range)	-2.34 (-1.11-3.43)
ALBI grade
Grade 1	7 (23.3)
Grade 2	21 (70)
Grade 3	2 (6.7)
Number of liver lesions
One	22 (73.3)
Two	6 (20)
Three	1 (3.3)
Four	1 (3.3)
Thrombus classification (Japanese)
VP2	1 (3.3)
VP3	8 (26.7)
VP4	18 (60)
VV2	1 (3.3)
VV3	2 (6.7)
Prior focal treatment
TACE	7 (23.3)
TARE	5 (16.7)
RFA	2 (6.7)
Cryoablation	1 (3.3)
Prior systemic therapy
Sorafenib	6 (20)
Lenvatinib	16 (53.3)
Atezolizumab + bevacizumab	1 (3.3)
Baseline AST (IU/mL) (mean ± SD)	46 ± 12
Baseline ALT (IU/mL) (mean ± SD)	49 ± 15

ALBI: Albumin-Bilirubin; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; RFA: Radiofrequency ablation; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.